BioPharm International Editors

Caribou and JAX entered into a license agreement for Caribou’s CRISPR-Cas9 gene editing technology.

The Czech Republic drug manufacturer was cited for data integrity and quality issues.

Heat Biologics will collaborate with the University of Miami on the development of a Zika vaccine using the company’s gp96 platform.

GENCO, a FedEx Company, introduces a multi-tenant warehouse model in Milton, Ontario, and Memphis, Tennessee.

IDT Biologika will provide fill/finish services of live-vectored virus products in clinical development through licensure.

Catalent invests $34 million to add a 2 x 2000-L single-use bioreactor system and laboratory space in Madison, WI.

Horizon announces new bioproduction outlicense deal with an unnamed partner for a minimum value of £500,000.

Insulin has been shown to improve the production of viruses and viral vectors.

Prefilled syringes for commercial supply of the etanercept biosimilar will be produced at Catalent’s Brussels facility in Belgium.

Oxford Genetics increased its laboratory space to 5700 sq. ft. with a move to a new location at Oxford Science Park.

The new guidelines will address bioanalytical method validation and biopharmaceutics classification system-based biowaivers.

The company announced plans to begin shipping Inflectra to the US market in late November 2016.

A €15-million investment will be made over 2014-2016 in a biotech facility located in Tres Cantos, Spain

The agency awarded 21 new clinical trial research grants to boost the development of treatments for rare diseases.

FDA is working with EMA to treat rare diseases and keep patients involved in healthcare.

Recipharm announced that it has invested 5 million SEK in a new GLP bioanalysis laboratory in Uppsala.

The companies will collaborate the manufacture of personalized cancer vaccines.

Wallace Cameron International was cited for not registering its Wishaw, Scotland facility with FDA.

Laboratoire Sintyl S.A. received an FDA warning letter for CGMP quality violations.

The company invested more than CHF 100 million in a new Delaware manufacturing plant.

HHS entered into a contract with BioProtection Systems Corp. for commercial manufacturing tests of an Ebola vaccine.

Marken announced the opening of a new depot and logistics operations center in Argentina.

The companies entered into a collaboration and license agreement for Crescendo’s Humabody-based therapeutics.

The agency’s Patient-Focused Drug Development program completed its commitment ahead of schedule.

WuXi AppTec’s new biomanufacturing facility is its third facility in the Philadelphia, PA Navy Yard.

The companies are collaborating on the commercialization of two biosimilar candidates in the US and Canada.

A report from the European Union Intellectual Property Office shows that the EU loses approximately €10.2 billion a year due to counterfeit medicines.

The company announced that it will build a new manufacturing facility at the GMR Aerospace Park at the Rajiv Gandhi International Airport in India.

Constantia Flexibles acquired a flexible packaging business from Lamp San Prospero SPA.

Xellia added laboratory space and personnel in Zagreb, Croatia to work on anti-infective products that combat the antimicrobial resistance problem.